Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis ; volume:12 ; number:1 ; year:2019 ; pages:59-62
Case reports in oncology ; 12, Heft 1 (2019), 59-62
- Creator
-
Wan, King Man
Oehler, Martin K.
- DOI
-
10.1159/000496198
- URN
-
urn:nbn:de:101:1-2019051600532179978843
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wan, King Man
- Oehler, Martin K.
Other Objects (12)
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Endocarditis following ocrelizumab in relapsing-remitting MS
Postural Control in Relapsing-Remitting Multiple Sclerosis
Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Relapsing/remitting type 1 diabetes
Long-lasting severe anemia following treatment with natalizumab for relapsing–remitting multiple sclerosis: a case report
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
Endocarditis following ocrelizumab in relapsing-remitting MS